Serum Cytokines and the Eosinophilia Myalgia Syndrome
Authors: Daniel J. Clauw, Leila H. Zackrison, Paul Katz
Journal: Annals of Internal Medicine (1992)

Letters15 August 1992Serum Cytokines and the Eosinophilia Myalgia SyndromeDaniel J. Clauw, MD, Leila H. Zackrison, MD, Paul Katz, MDDaniel J. Clauw, MDSearch for more papers by this author, Leila H. Zackrison, MDSearch for more papers by this author, Paul Katz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-117-4-344 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the Editors: Varga and colleagues (1) outline many of the recent advances in our understanding of the eosinophilia myalgia syndrome (EMS). Current theories about the pathogenesis of this disease include direct toxic effects from both eosinophil products and tryptophan metabolites as well as effects mediated by activated T cells, monocytes, and fibroblasts.Because serum cytokine elevation is known to be related to an activated immune system, we compared the levels of serum cytokines with clinical disease activity in patients with EMS. Sixty-eight serum samples from twenty patients fulfilling the Centers for Disease Control (CDC) criteria for the diagnosis of...References1. VargaUittoJimenez JJS. The cause and pathogenesis of the eosinophilia-myalgia syndrome. Ann Intern Med. 1992;116:140-7. LinkGoogle Scholar2. KaufmanGruberNeedleman LBB. Interleukin-4 levels in the eosinophilia-myalgia syndrome. Am J Med. 1991;91:664-5. CrossrefMedlineGoogle Scholar3. OwenPetersenSheffFolkerthAndersonCorson WJDRRJ. Hypodense eosinophils and interleukin 5 activity in the blood of patients with the eosinophilia-myalgia syndrome. Proc Natl Acad Sci USA. 1990;87:8647-51. CrossrefMedlineGoogle Scholar4. Silver R. The eosinophilia-myalgia syndrome. Mediguide to Inflammatory Diseases. 1991;10:1-5. Google Scholar5. NeedlemanWigleyStair BFR. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor-alpha, and interfer-on-gammalevels in sera from patients with scleroderma. Arthritis Rheum. 1992;359:67-72. CrossrefGoogle Scholar1. ReitamoRemitzVarga SAJ. Demonstration of IL-8 and autoantibodies to IL-8 in sera of patients with systemic sclerosis (SSc) and related disorders. J Invest Dermatol. 1992;98:615. Google Scholar2. KaufmanGruberNeedleman LBB. Interleukin-4 levels in the eosinophilia-myalgia syndrome. Am J Med. 1991;91:664-5. CrossrefMedlineGoogle Scholar3. OwenPetersenSheffFolkerthAndersonCorson WJDRRJ. Hypodense eosinophils and interleukin-5 activity in the blood of patients with the eosinophilia-myalgia syndrome. Proc Natl Acad Sci USA. 1991;87:8647-51. CrossrefGoogle Scholar4. Falanga V. Observations in the potential role of TGFß in cutaneous fibrosis. Ann NY Acad Sci. 1990;593:161-71. CrossrefMedlineGoogle Scholar5. NeedlemanWigleyStair BFR. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor-alpha, and interfer-on-gammalevels in sera from patients with scleroderma. Arthritis Rheum. 1992;35:67-72. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Georgetown University Medical Center Washington, D.C. 20007-2197 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByEosinophilia-Myalgia Syndrome, Eosinophilic Fasciitis, and Related Fasciitis DisordersThe Eosinophilia Myalgia SyndromeViruses and Chronic Fatigue SyndromeTHE EVOLVING SPECTRUM OF EOSINOPHILIA MYALGIA SYNDROME 15 August 1992Volume 117, Issue 4Page: 344-345KeywordsCytokinesEosinophilia myalgia syndromeEosinophilsFibroblastsImmune systemMetabolitesMonocytesPathogenesisT cellsTryptophan Issue Published: 15 August 1992 PDF DownloadLoading ...